CVRx (CVRX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
1 Jun, 2026Opening remarks and agenda
Meeting commenced at 10 A.M. Central Time with all board members and the independent auditor present.
Notice of the meeting was sent to stockholders on April 20, 2026.
Stockholders could vote or change votes during the meeting and submit questions electronically.
Board and executive committee updates
Three class 2 directors were up for election for a three-year term.
Michael Dale, Joseph Slattery, and Kevin Hykes were elected as directors by plurality vote.
Corporate governance
Quorum was established with a majority of outstanding shares represented.
Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Jared Oasheim, CFO, served as inspector of elections and certified the voting.
Latest events from CVRx
- Execution improvements and payer wins position the therapy for broader adoption and growth.CVRX
Canaccord Genuity's 46th Annual Growth Conference - Q2 revenue up 16% year-over-year, but full-year outlook lowered amid sales and payer headwinds.CVRX
Q2 2026 - Barostim therapy gains momentum with expanded access, strong evidence, and accelerating U.S. growth.CVRX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Barostim's clinical success and new coverage drive heart failure market expansion and access.CVRX
46th Annual William Blair Growth Stock Conference - Q1 2026 revenue rose 20% with strong U.S. growth, margin gains, and market expansion efforts.CVRX
Q1 2026 - Votes are sought for three director nominees and auditor ratification at the 2026 annual meeting.CVRX
Proxy filing - Q4 revenue up 4%, gross margin at 86%, and BENEFIT-HF trial to triple market size.CVRX
Q4 2025 - Refined strategy, reimbursement wins, and expanded market position set the stage for accelerated growth.CVRX
Piper Sandler 36th Annual Healthcare Conference - Q3 revenue up 27% to $13.4M, with Barostim adoption, reimbursement gains, and strong cash reserves.CVRX
Q3 2024